Metal-Organic Framework-Integrated Nanoplatform Orchestrates Osteochondral-Synovial Homeostasis for Osteoarthritis

Hongwei Shao1,2, Shunxiang Xu1,2, Fanchu Zeng1,2

  • 1Musculoskeletal Research Laboratory, Department of Orthopaedics & Traumatology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR 999077, P. R. China.

ACS Nano
|September 1, 2025
PubMed

Insights

A novel nanoplatform, CLKM, effectively treats osteoarthritis (OA) by protecting cartilage, modulating inflammation, and promoting tissue repair. This breakthrough offers a promising therapeutic strategy for managing OA progression.

Area of Science:

  • Biomaterials Science
  • Nanotechnology
  • Orthopedics

Background:

  • Osteoarthritis (OA) presents a significant clinical challenge due to complex cartilage degradation, synovitis, and subchondral bone changes.
  • Current intra-articular therapies for OA face limitations including rapid clearance, poor cartilage penetration, and lack of multifactorial targeting.

Purpose of the Study:

  • To engineer a hybrid nanoplatform (CLKM) for synergistic, multi-action OA therapeutics.
  • To integrate boundary lubrication and an osteochondral-synovial synergistic effect for enhanced OA treatment.

Main Methods:

  • Development of a CLKM nanoplatform: kartogenin (KGN)-loaded Mg/Zn-based metal-organic framework (Mg-ZIF) core within a cartilage affinity peptide-conjugated lubricant liposome (CAP-Lipo) shell.
  • Evaluation of CLKM's chondrocyte uptake, cartilage penetration, joint retention, and therapeutic effects in OA mouse models (surgery-induced and post-traumatic OA).
  • Assessment of CLKM's impact on chondrocyte apoptosis, catabolic metabolism, synovial macrophage phenotype, osteoclastogenesis, stem cell recruitment, and chondrogenesis.

Main Results:

  • CLKM demonstrated enhanced chondrocyte uptake, deep cartilage penetration, and prolonged joint retention.
  • CLKM suppressed chondrocyte apoptosis and catabolic activity, reprogrammed synovial macrophages to a reparative phenotype, and inhibited osteoclastogenesis.
  • CLKM promoted stem cell recruitment and chondrogenesis, leading to cartilage structural repair, preservation of cartilage integrity, reduced synovitis, normalized subchondral bone remodeling, and restored gait symmetry in OA mice.

Conclusions:

  • The CLKM nanoplatform effectively orchestrates chondroprotection, immunomodulation, and tissue remodeling to disrupt the OA vicious cycle.
  • CLKM offers a promising and versatile therapeutic strategy for managing osteoarthritis progression and improving joint function.